Gene Therapy Market Summary

• The Gene Therapy market size is estimated at USD 9.5 billion in 2025 and is projected to reach USD 45.2 billion by 2034. Growth is anchored in a rapid wave of regulatory approvals, the curative potential of one-time treatments for previously untreatable genetic diseases and cancers, and sustained investment in viral vector and gene editing platforms.
• The global Gene Therapy market is growing at a CAGR of 18.9% during the forecast period from 2026 to 2034.
• By vector type, the viral vectors segment dominated the Gene Therapy market with a 78% share in 2025.
• By delivery method, the in vivo segment dominated the Gene Therapy market with a share of 58% in 2025.
• By application, the oncology segment dominated the Gene Therapy market with a share of 42% in 2025.
• By end-user, the hospitals segment dominated the Gene Therapy market with a share of 54% in 2025.
• North America dominated the global Gene Therapy market revenue with a share of 46% in 2025, representing the highest regional market share globally.

Gene therapy is a class of advanced therapeutic medicinal products that treat or prevent disease by introducing, correcting, replacing, inactivating, or editing genetic material within a patient's cells, rather than addressing symptoms with conventional drugs. The category spans in vivo approaches, in which a therapeutic gene is delivered directly into the body, and ex vivo approaches, in which a patient's cells are genetically modified outside the body and reinfused, and it relies on delivery vehicles that include adeno-associated virus, lentiviral, retroviral, and adenoviral vectors alongside emerging non-viral and gene editing systems such as CRISPR. A complete gene therapy value chain integrates vector design and manufacturing, gene construct development, delivery, and specialized administration at qualified treatment centers, supported by long-term patient monitoring. Over the past decade, gene therapy has advanced from experimental research into an approved clinical reality, with landmark products addressing inherited retinal disease, spinal muscular atrophy, hemophilia, sickle cell disease, beta thalassemia, muscular dystrophy, and metachromatic leukodystrophy, transforming the treatment of rare genetic disorders and oncology and establishing a durable, high-value therapeutic market.

Gene Therapy Market Key Growth Drivers

• The accelerating pace of regulatory approvals is expanding the commercial market, with the Alliance for Regenerative Medicine recording 10 cell and gene therapy approvals in 2024 following landmark 2023 approvals such as Casgevy, the first CRISPR-based medicine.
• The high and rising burden of rare genetic disorders is driving demand, with an estimated 7,000 rare diseases affecting around 300 million people worldwide, the majority of which have a genetic origin and lack curative treatment options.
• The growing global cancer burden is expanding gene therapy oncology applications, with the International Agency for Research on Cancer reporting 20 million new cancer cases in 2022 and projecting 35 million by 2050.
• The curative, one-time treatment value proposition of gene therapy is attracting strong clinical and payer interest despite high upfront costs, reshaping treatment paradigms for chronic genetic diseases.
• Sustained investment and a deep clinical pipeline are fueling growth, with the Alliance for Regenerative Medicine tracking 1,968 clinical trials and 2,981 developers active in the sector as of 2024.
• Technological advances in adeno-associated virus vector engineering, lentiviral delivery, and CRISPR-based gene editing are improving safety, targeting, and manufacturability, broadening the range of treatable conditions.
• The convergence of expanding approvals, rising disease burden, curative potential, and platform innovation is expected to sustain strong double-digit growth in the global Gene Therapy market through 2034.

Key Companies in Gene Therapy Market

The competitive landscape is led by the following active developers and manufacturers of approved gene therapies:

• Novartis AG
• F. Hoffmann-La Roche Ltd (Spark Therapeutics, Inc.)
• Vertex Pharmaceuticals Incorporated
• CSL Limited (CSL Behring)
• BioMarin Pharmaceutical Inc.
• Sarepta Therapeutics, Inc.
• Pfizer Inc.
• uniQure N.V.
• Krystal Biotech, Inc.
• REGENXBIO Inc., and others

For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.

Gene Therapy Market Size

The following snapshot summarizes the principal report metrics for the Gene Therapy market.

All market values are expressed in USD and represent DelveInsight estimates synthesized from primary and secondary research.

Factors Contributing to the Growth of the Gene Therapy Market

Gene Therapy Market Drivers

• Accelerating Regulatory Approvals Expanding the Commercial Market: A rapid wave of regulatory approvals is the primary catalyst transforming gene therapy from an experimental field into a commercial market. The Alliance for Regenerative Medicine recorded 10 cell and gene therapy approvals in 2024, spanning indications including metachromatic leukodystrophy, hemophilia B, sickle cell disease, and beta thalassemia, following landmark 2023 approvals such as Casgevy, the first CRISPR-based medicine. Regulatory agencies have created dedicated pathways to speed access, including the United States Food and Drug Administration's Regenerative Medicine Advanced Therapy designation and the European Medicines Agency's PRIME scheme, which provide enhanced guidance and expedited review for transformative therapies. Each approval opens a new commercial indication, establishes reimbursement precedent, and validates the underlying vector or editing platform for follow-on products. As multiple therapies now compete within indications such as hemophilia B and beta thalassemia, the market is maturing from single-product categories into competitive therapeutic areas. The expanding base of approved products, reinforced by expedited regulatory frameworks and a robust late-stage pipeline, is expected to drive sustained revenue growth across the forecast period.
• Rising Burden of Rare Genetic Disorders: The large and largely unmet burden of rare genetic disorders is a fundamental driver of gene therapy demand. An estimated 7,000 rare diseases affect around 300 million people worldwide, and the majority have a genetic origin, yet only a small fraction have approved treatments. Gene therapy is uniquely suited to these monogenic conditions, offering the potential to correct the underlying genetic defect with a single intervention. Approved therapies now address inherited retinal disease, spinal muscular atrophy, hemophilia A and B, metachromatic leukodystrophy, and dystrophic epidermolysis bullosa, demonstrating clinical benefit in diseases that previously had limited or no disease-modifying options. Patient advocacy, improved genetic diagnosis, and newborn screening are increasing identification of eligible patients, expanding the addressable population. As the scientific understanding of monogenic disease deepens and diagnostic capacity improves, the pool of treatable rare genetic conditions continues to widen, sustaining strong demand for gene therapy and encouraging continued development across a broad range of indications through 2034.
• Growing Global Cancer Burden and Expansion into Oncology: The rising global cancer burden is expanding the application of gene therapy in oncology. According to the International Agency for Research on Cancer, approximately 20 million new cancer cases were diagnosed in 2022, with cases projected to reach 35 million by 2050. Gene-modified cell therapies and in vivo genetic approaches are increasingly used to treat hematologic malignancies and are advancing into solid tumors, offering targeted and potentially durable responses in patients who have exhausted conventional options. The success of gene-modified therapies in leukemia, lymphoma, and myeloma has established oncology as the largest gene therapy application and has attracted substantial investment into next-generation constructs, in vivo delivery, and allogeneic approaches designed to broaden access. As cancer incidence rises and gene therapy platforms extend to additional tumor types, oncology is expected to remain a major growth engine for the market, reinforcing the leadership of the application segment and driving continued clinical and commercial expansion across the forecast period.
• Curative Potential and One-Time Treatment Value Proposition: The curative, one-time treatment value proposition of gene therapy is reshaping treatment paradigms and attracting clinical and payer interest. Unlike chronic therapies that require lifelong administration, gene therapies aim to deliver durable or potentially permanent benefit from a single treatment, addressing the root genetic cause of disease. This proposition is particularly compelling for severe, progressive conditions where the cumulative cost and burden of chronic management are high. Payers and health systems are developing innovative reimbursement models, including outcomes-based agreements and installment arrangements, to align payment with long-term benefit and manage the high upfront cost of these therapies. The demonstrated durability of several approved products has strengthened confidence in the long-term value of gene therapy, supporting its integration into treatment guidelines. As real-world evidence on durability accumulates and payment models mature, the curative value proposition is expected to accelerate adoption and support premium pricing across the forecast period.
• Sustained Investment and a Deep Clinical Pipeline: Robust investment and an expansive clinical pipeline are underpinning long-term market growth. The Alliance for Regenerative Medicine tracked 1,968 clinical trials and 2,981 developers active in the cell and gene therapy sector as of 2024, reflecting broad scientific and commercial momentum. Capital continues to flow into vector engineering, gene editing, and manufacturing, supporting both established developers and a large field of emerging biotechnology companies. Strategic partnerships, licensing deals, and acquisitions by large pharmaceutical companies are consolidating platform capabilities and de-risking development, while contract development and manufacturing organizations are expanding capacity to address supply constraints. The depth and diversity of the pipeline, spanning rare genetic disorders, oncology, neurology, ophthalmology, and hematology, provide a durable stream of potential approvals. This sustained investment and pipeline breadth are expected to translate into a growing number of commercial products and expanding revenue across the forecast period.
• Advances in Viral Vector and Gene Editing Technologies: Continuous technological innovation is enhancing the safety, precision, and manufacturability of gene therapy. Advances in adeno-associated virus capsid engineering are improving tissue targeting and reducing immunogenicity, while lentiviral and retroviral systems continue to enable durable ex vivo modification of patient cells. The clinical maturation of CRISPR-based gene editing, exemplified by the approval of the first CRISPR medicine, has opened a new therapeutic modality with the potential to correct or disrupt disease-causing sequences directly. Emerging approaches, including base editing, prime editing, epigenetic editing, and in vivo delivery of editing components, are expanding the range of addressable diseases and have entered clinical testing during 2024. Parallel progress in manufacturing, analytics, and non-viral delivery is improving scalability and cost. These technological advances are broadening the universe of treatable conditions, improving product profiles, and lowering development barriers, reinforcing sustained market growth and competitive innovation through 2034.
• Supportive Regulatory Frameworks and Expedited Pathways: Supportive regulatory frameworks are lowering barriers and accelerating the path to market for gene therapies. Agencies including the United States Food and Drug Administration and the European Medicines Agency have established dedicated designations and expedited pathways, such as Regenerative Medicine Advanced Therapy, Breakthrough Therapy, PRIME, and accelerated approval, that provide intensive guidance and faster review for products addressing serious diseases. Orphan drug incentives, including market exclusivity and development support, further encourage investment in rare genetic conditions that constitute the majority of gene therapy targets. Regulators have also issued detailed guidance on manufacturing, potency, and long-term follow-up, providing developers with greater clarity and reducing development uncertainty. These frameworks shorten timelines, improve the predictability of development, and signal institutional commitment to advanced therapies. As regulatory science continues to evolve alongside the field, expedited and adaptive pathways are expected to remain a significant enabler of market growth across the forecast period.

Gene Therapy Market Restraints

Despite strong momentum, the Gene Therapy market faces material constraints. High treatment costs are the most visible barrier, with several therapies priced in the millions of dollars, including Lenmeldy at USD 4.25 million and Hemgenix at USD 3.5 million, straining payer budgets and complicating patient access. Reimbursement and access remain uneven, as health systems grapple with paying for durable but expensive one-time treatments, and outcomes-based and installment models are still maturing. Manufacturing complexity is a persistent challenge, since viral vector production and ex vivo cell modification are technically demanding, capacity-constrained, and costly, exposing developers to supply and scale-up risk. Regulatory complexity is significant, as products must satisfy evolving requirements for potency, comparability, and long-term follow-up, lengthening development timelines. Clinical challenges persist, including pre-existing immunity to viral vectors, immunogenic responses, uncertain long-term durability, and the risk of adverse events, which have prompted safety reviews and, in some cases, program discontinuations. Logistical demands are substantial, requiring specialized administration at qualified treatment centers, cold chain handling, and coordination across the care pathway. A shortage of skilled manufacturing and clinical personnel further constrains capacity, while limited eligible patient populations for individual rare indications and uneven adoption outside major markets restrain the pace of global expansion.

Gene Therapy Market Segment Analysis

The Gene Therapy Market is segmented by vector type (viral vectors, non-viral vectors), delivery method (in vivo, ex vivo), application (oncology, rare genetic disorders, neurological disorders, ophthalmology, hematological disorders, others), end-user (hospitals, specialty and ambulatory treatment centers, academic and research institutes, others), and geography (North America, Europe, Asia-Pacific, Rest of World).

By Vector Type

Dominant Subsegment: Viral Vectors.

The viral vectors segment accounted for 78% of the Gene Therapy market in 2025. Viral vectors dominate because they provide the most efficient and clinically validated means of delivering genetic material into human cells, and nearly all approved gene therapies rely on them. Adeno-associated virus vectors underpin leading in vivo products such as those for spinal muscular atrophy, inherited retinal disease, and hemophilia, valued for their favorable safety profile and durable expression, while lentiviral and retroviral vectors enable durable ex vivo modification for hematologic and metabolic diseases, including sickle cell disease and metachromatic leukodystrophy. The segment's leadership is reinforced by decades of engineering that have improved capsid targeting, transduction efficiency, and manufacturability, and by a deep pipeline built predominantly on viral delivery. Continued innovation in capsid design and vector manufacturing is expanding tissue targeting and reducing immunogenicity, supporting new indications. Regulatory familiarity with viral vector products further lowers development risk. While non-viral vectors and emerging delivery systems are advancing rapidly and offer advantages in manufacturability and redosing, viral vectors retain dominance through their proven efficacy, durability, and entrenched clinical validation across the forecast period.

By Delivery Method

Dominant Subsegment: In Vivo.

The in vivo segment accounted for 58% of the Gene Therapy market in 2025. In vivo gene therapy, in which the therapeutic gene is delivered directly into the patient's body, dominates because it underpins several of the highest-revenue approved products, including therapies for spinal muscular atrophy, inherited retinal disease, hemophilia, and muscular dystrophy. The approach is generally less complex to administer than ex vivo therapy, since it does not require harvesting, modifying, and reinfusing a patient's cells, broadening the range of treatment settings and eligible patients. Adeno-associated virus vectors are the primary delivery vehicle for in vivo therapy, and ongoing advances in capsid engineering are improving targeting and expanding the tissues that can be reached. The scalability and relative operational simplicity of in vivo administration support its commercial leadership. Ex vivo gene therapy remains essential for hematologic and metabolic diseases and is growing strongly, propelled by gene-edited products such as those for sickle cell disease and beta thalassemia, but in vivo delivery retains its leading share in 2025 on the strength of its established, high-value product base across the forecast period.

By Application

Dominant Subsegment: Oncology.

The oncology segment accounted for 42% of the Gene Therapy market in 2025. Oncology is the leading application because gene-modified cell therapies and in vivo genetic approaches have achieved durable responses in hematologic malignancies and are expanding into additional tumor types. The International Agency for Research on Cancer recorded 20 million new cancer cases in 2022 and projects 35 million by 2050, enlarging the population that may benefit from advanced genetic treatments. Gene-modified therapies targeting leukemia, lymphoma, and myeloma have established a commercial foundation, and substantial investment is advancing next-generation constructs, in vivo delivery, and allogeneic approaches designed to broaden access and reduce cost. The breadth of oncology pipelines and the severity of unmet need sustain the segment's leadership. Rare genetic disorders represent the next-largest application and are growing rapidly as approvals expand across inherited diseases, while neurological, ophthalmology, and hematological applications add further demand. The combination of rising cancer incidence, clinical success in blood cancers, and expansion into solid tumors secures oncology's leadership across the forecast period.

By End-User

Dominant Subsegment: Hospitals.

The hospitals segment accounted for 54% of the Gene Therapy market in 2025. Hospitals, particularly academic medical centers and qualified treatment centers, dominate because gene therapies require specialized administration, intensive monitoring, and multidisciplinary care that these institutions are uniquely equipped to provide. Many approved therapies, especially ex vivo products, involve complex procedures such as cell collection, conditioning, and reinfusion, along with management of potential adverse events, that must be delivered in accredited hospital settings. Manufacturers restrict administration to certified centers with the necessary infrastructure, expertise, and cold chain capabilities, concentrating volume in hospitals. These institutions also serve as sites for clinical trials and early adoption of newly approved therapies, reinforcing their central role. Specialty and ambulatory treatment centers are expanding as certain in vivo therapies become more straightforward to administer, and academic and research institutes remain important for development and early clinical use. Nonetheless, hospitals retain leadership in 2025 on the strength of their capacity to deliver complex, high-acuity gene therapy safely across the forecast period.

Gene Therapy Market Region Analysis

Dominant Region: North America

North America accounted for 46% of the global Gene Therapy market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects the concentration of gene therapy developers, academic medical centers, and qualified treatment centers in the United States, together with the most developed regulatory and reimbursement environment for advanced therapies. Market-size influence is amplified by early access to a broad portfolio of approved products and by strong per-patient revenue given premium pricing. Healthcare infrastructure is mature, with accredited centers capable of delivering complex ex vivo and in vivo therapies and managing long-term follow-up. The regulatory environment is highly supportive, with the Food and Drug Administration providing expedited pathways such as Regenerative Medicine Advanced Therapy designation and a track record of landmark approvals, including the first CRISPR-based medicine in 2023. The investment landscape is strong, with the Alliance for Regenerative Medicine recording the largest share of sector financing in North America, sustained by both private capital and public research funding from agencies such as the National Institutes of Health. A dense base of leading developers, including Novartis, Vertex Pharmaceuticals, Sarepta Therapeutics, and BioMarin, further reinforces North America's leadership.

Fastest Growing Region: Asia-Pacific

Asia-Pacific is the fastest-growing region in the Gene Therapy market. The region's elevated CAGR is driven by rising healthcare investment, expanding clinical research capacity, and growing government support for advanced therapies across China, Japan, India, South Korea, and Australia. National initiatives and regulatory reforms are creating expedited pathways for regenerative medicine, while Japan's established framework for conditional approval of advanced therapies has encouraged development. A large patient population, increasing genetic diagnosis, and rising cancer and rare disease burden are expanding the addressable market. Domestic biotechnology companies and manufacturing capacity are scaling rapidly, and the Alliance for Regenerative Medicine has noted growing sector investment in the region. International collaborations, technology transfer, and local clinical trials are accelerating access, positioning Asia-Pacific as the highest-growth region over the forecast period.

Gene Therapy Market Regional Commentary

North America

North America accounted for 46% of the global Gene Therapy market revenue in 2025. The United States dominates the region on the strength of its developer base, network of qualified treatment centers, expedited regulatory pathways, and reimbursement innovation, while Canada advances through public funding and access frameworks for high-cost therapies and Mexico expands specialized treatment capacity within its private healthcare sector.

Europe

Europe represents the second-largest regional market, led by Germany, the United Kingdom, and France. Growth is supported by centralized European Medicines Agency approval of advanced therapy medicinal products, the PRIME scheme for priority medicines, national reimbursement initiatives, and strong academic and clinical infrastructure, alongside managed-access agreements that address the high cost of gene therapies.

Asia-Pacific

Asia-Pacific is the fastest-growing region, propelled by healthcare investment, expanding research activity, and supportive regulatory reforms across China, Japan, India, South Korea, and Australia. Japan's conditional approval framework, a large patient population, and rapidly scaling domestic manufacturing are broadening access to advanced therapies beyond major urban centers.

Rest of World

The Rest of World region, spanning the Middle East, Africa, and South America, is an emerging growth frontier. Rising healthcare investment, national initiatives for rare disease and advanced therapy access, and international collaborations are expanding availability, while improving diagnostic and treatment infrastructure gradually broadens the eligible patient population.

Gene Therapy Market Competitive Landscape

The Gene Therapy market is classified as Moderately Concentrated. A group of large pharmaceutical and specialized biotechnology companies holds the majority of commercial revenue through approved products, led by Novartis, Roche through Spark Therapeutics, Vertex Pharmaceuticals, CSL Behring, BioMarin, Sarepta Therapeutics, and Pfizer, while a broad and fragmented field of emerging developers competes across an extensive clinical pipeline supported by vector and gene editing platform specialists. The competitive landscape can be evaluated across the following dimensions:

• Market concentration: Moderately concentrated, with commercial revenue held by a few approved-product leaders alongside a large, fragmented clinical pipeline of emerging developers.
• Leading players: Novartis, Vertex Pharmaceuticals, Roche (Spark Therapeutics), CSL Behring, BioMarin, Sarepta Therapeutics, and Pfizer anchor the top tier.
• Geographic reach: Leaders operate global development and commercial networks, with qualified treatment centers concentrated in North America and Europe and expansion into Asia-Pacific.
• Product portfolio strength: Top players hold approved therapies across hemophilia, spinal muscular atrophy, sickle cell disease, muscular dystrophy, and inherited retinal disease.
• Pipeline strength: Deep pipelines in rare genetic disorders, oncology, neurology, and ophthalmology, increasingly incorporating gene editing and in vivo delivery.
• Strategic partnerships: Collaborations among pharmaceutical companies, platform biotechs, and contract manufacturers extend capability and de-risk development.
• M&A activity: Consolidation continues as large pharmaceutical companies acquire platform and product assets to build advanced therapy franchises.
• Manufacturing capabilities: Viral vector production and ex vivo processing are key competitive moats and significant capacity and supply-chain risks.
• Innovation focus: CRISPR and next-generation gene editing, improved AAV capsids, non-viral delivery, and scalable, lower-cost manufacturing.

Gene Therapy Market Recent Developmental Activities

• In April 2024, Pfizer Inc. received FDA approval for Beqvez (fidanacogene elaparvovec), an adeno-associated virus gene therapy for adults with moderate to severe hemophilia B. Strategic significance: Expands the approved hemophilia B options and strengthens large-pharmaceutical presence in in vivo gene therapy, intensifying competition in the indication.
• In March 2024, Orchard Therapeutics (a Kyowa Kirin company) launched Lenmeldy (atidarsagene autotemcel) in the United States at USD 4.25 million, becoming the world's most expensive medicine, for early-onset metachromatic leukodystrophy. Strategic significance: Demonstrates both the curative promise and the pricing and access challenges that define the gene therapy market.
• In January 2024, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG received expanded FDA approval of Casgevy for transfusion-dependent beta thalassemia, following its December 2023 approval for sickle cell disease. Strategic significance: Establishes the first CRISPR gene editing medicine across two indications, validating gene editing as a commercial therapeutic modality.
• In December 2023, Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG received FDA approval of Casgevy (exagamglogene autotemcel) for sickle cell disease, the first CRISPR-based medicine approved in the United States. Strategic significance: Marks a historic milestone that opens the gene editing era and reshapes the competitive and technological landscape.
• In December 2023, Bluebird Bio, Inc. received FDA approval of Lyfgenia (lovotibeglogene autotemcel), a lentiviral gene therapy for sickle cell disease. Strategic significance: Provides a second approved gene therapy for sickle cell disease, establishing a competitive indication and expanding patient options.
• In June 2024, Sarepta Therapeutics, Inc. received expanded FDA approval for Elevidys (delandistrogene moxeparvovec) in Duchenne muscular dystrophy, broadening the eligible patient population beyond the initial 2023 approval. Strategic significance: Enlarges the addressable market for the first gene therapy for Duchenne muscular dystrophy and reinforces Sarepta's leadership in the indication.
• In 2024, the Alliance for Regenerative Medicine reported 10 cell and gene therapy approvals for the year and tracked 1,968 clinical trials and 2,981 developers in the sector. Strategic significance: Confirms the accelerating pace of approvals and the depth of the pipeline sustaining long-term market growth.
• In May 2023, Krystal Biotech, Inc. received FDA approval of Vyjuvek (beremagene geperpavec), the first redosable, topically administered gene therapy, for dystrophic epidermolysis bullosa. Strategic significance: Introduces a novel redosable delivery model and expands gene therapy into chronic skin disease, broadening the modality's applications.
• In November 2022, CSL Limited (CSL Behring), in partnership with uniQure N.V., launched Hemgenix (etranacogene dezaparvovec) for hemophilia B at USD 3.5 million. Strategic significance: Established a landmark high-value in vivo gene therapy and a benchmark for pricing and reimbursement of one-time curative treatments.
• In 2024, in vivo gene editing advanced into the clinic, with the first patients dosed with in vivo CAR gene therapy and in vivo mRNA CAR therapy, alongside the clinical debut of prime editing and epigenetic editing. Strategic significance: Signals the next technological wave that could broaden addressable diseases and reshape competitive dynamics.
• In 2024 and 2025, health systems and manufacturers expanded outcomes-based and installment reimbursement agreements for high-cost gene therapies to improve patient access. Strategic significance: Addresses the central affordability barrier and supports commercial uptake of durable one-time treatments.
• In 2023 and 2024, contract development and manufacturing organizations expanded viral vector and cell processing capacity to relieve supply constraints across the sector. Strategic significance: Strengthens the manufacturing base that underpins commercial scale-up and reduces a key bottleneck to market growth.

Gene Therapy Market Segmentation

• Gene Therapy Market by Vector Type
  • Viral Vectors (Adeno-associated Virus, Lentiviral, Retroviral, Adenoviral, Others)
  • Non-viral Vectors
• Gene Therapy Market by Delivery Method
  • In Vivo
  • Ex Vivo
• Gene Therapy Market by Application
  • Oncology
  • Rare Genetic Disorders
  • Neurological Disorders
  • Ophthalmology
  • Hematological Disorders
  • Others
• Gene Therapy Market by End-User
  • Hospitals
  • Specialty and Ambulatory Treatment Centers
  • Academic and Research Institutes
  • Others

Gene Therapy Market Assessment by Geography

• North America Gene Therapy Market Assessment
  • United States Gene Therapy Market Size in USD million (2023-2034)
  • Canada Gene Therapy Market Size in USD million (2023-2034)
  • Mexico Gene Therapy Market Size in USD million (2023-2034)
  • Europe Gene Therapy Market Assessment
• Germany Gene Therapy Market Size in USD million (2023-2034)
  • United Kingdom Gene Therapy Market Size in USD million (2023-2034)
  • France Gene Therapy Market Size in USD million (2023-2034)
  • Italy Gene Therapy Market Size in USD million (2023-2034)
  • Spain Gene Therapy Market Size in USD million (2023-2034)
  • Rest of Europe Gene Therapy Market Size in USD million (2023-2034)
• Asia-Pacific Gene Therapy Market Assessment
  • China Gene Therapy Market Size in USD million (2023-2034)
  • Japan Gene Therapy Market Size in USD million (2023-2034)
  • India Gene Therapy Market Size in USD million (2023-2034)
  • Australia Gene Therapy Market Size in USD million (2023-2034)
  • South Korea Gene Therapy Market Size in USD million (2023-2034)
  • Rest of Asia-Pacific Gene Therapy Market Size in USD million (2023-2034)
• Rest of the World (RoW) Gene Therapy Market Assessment
  • Middle East Gene Therapy Market Size in USD million (2023-2034)
  • Africa Gene Therapy Market Size in USD million (2023-2034)
  • South America Gene Therapy Market Size in USD million (2023-2034)

Gene Therapy Market Recent Industry Trends and Milestones (2023-2026):

Gene Therapy Market Startup Funding and Investment Trends

Investment in the Gene Therapy ecosystem has concentrated on gene editing and gene writing platforms, engineered delivery vectors, and scalable manufacturing. The following startups illustrate recent funding activity and technology focus.

Tessera Therapeutics is advancing a gene writing platform designed to add, edit, or rewrite genetic sequences with the goal of curing disease, while Dyno Therapeutics applies artificial intelligence to engineer next-generation adeno-associated virus capsids that improve targeting and manufacturability. Additional capital continues to flow toward gene editing, non-viral delivery, and manufacturing scale-up, reflecting investor conviction that the next sources of competitive advantage lie in precision editing, improved delivery, and lower-cost production. Collectively, these rounds signal sustained investment in expanding the range of treatable diseases, improving product safety and durability, and relieving the manufacturing constraints that limit access to gene therapy.

Key Takeaways from the Gene Therapy Market Report Study

• Market size analysis for the current gene therapy market size (2025), and market forecast for 9 years (2026 to 2034).
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
• Key companies dominating the global gene therapy market.
• Various opportunities available for competitors in the gene therapy market space.
• What are the top-performing segments in 2025? How will these segments perform in 2034?
• Which are the top-performing regions and countries in the current gene therapy market scenario?
• Which are the regions and countries where companies should concentrate their opportunities for gene therapy market growth in the future?

Target audience that can benefit from this gene therapy market report study

• Gene Therapy product providers
• Research organizations and consulting companies
• Gene Therapy-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in gene therapy
• Various end-users who want to know more about the gene therapy market and the latest technological developments in the gene therapy market.

Frequently Asked Questions

Q1. What is the growth rate of the Gene Therapy market?

The Gene Therapy market is projected to expand at a CAGR of 18.9% during the forecast period of 2026-2034.

Q2. What is the market size of the Gene Therapy market?

The Gene Therapy market size is estimated at USD 9.5 billion in 2025 and is projected to reach USD 45.2 billion by 2034.

Q3. Which region dominates the Gene Therapy market?

North America dominated the Gene Therapy market with a 46% share of global revenue in 2025, supported by a dense base of developers and qualified treatment centers, expedited FDA pathways such as Regenerative Medicine Advanced Therapy designation, early access to approved products, and sustained public and private investment. Asia-Pacific is the fastest-growing region over the forecast period.

Q4. What are the key drivers of the Gene Therapy market?

The principal drivers are the accelerating pace of regulatory approvals, with 10 cell and gene therapy approvals recorded in 2024 by the Alliance for Regenerative Medicine; the high burden of rare genetic disorders, with an estimated 7,000 rare diseases affecting around 300 million people worldwide; the rising global cancer burden, projected by the International Agency for Research on Cancer to increase from 20 million new cases in 2022 to 35 million by 2050; and advances in viral vector engineering and CRISPR-based gene editing, reinforced by the curative one-time treatment value proposition.

Q5. Who are the major players in the Gene Therapy market?

The leading Gene Therapy companies in the market include Novartis AG, F. Hoffmann-La Roche Ltd (Spark Therapeutics, Inc.), Vertex Pharmaceuticals Incorporated, CSL Limited (CSL Behring), BioMarin Pharmaceutical Inc., Sarepta Therapeutics, Inc., Pfizer Inc., uniQure N.V., Krystal Biotech, Inc., and REGENXBIO Inc., among other active developers and manufacturers profiled in the Competitive Landscape section. Vertex Pharmaceuticals leads gene editing therapy through Casgevy, while Novartis and Sarepta lead in vivo gene therapy.